Developing IMR-687, an IND-ready PDE9 (phosphodiesterase 9) inhibitor for sickle cell disease
- Year invested 2016
- Investment Stage Early
- Sectors
- Investment Status Current
- Website imaratx.com/patients-families/living-with-sickle-cell-disease/
- Company Status IPO/Public (NASDAQ: IMRA)